A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-16269110 in Overweight and Obese Subjects.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Usistapide (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 13 May 2014 Biomarkers information updated
- 16 Jul 2010 Results were reported at the 11th International Congress on Obesity.
- 29 Jan 2009 Actual patient numbers (321) added as reported by ClinicalTrials.gov.